Objective: To gain information about the indications for and complications of conventional nephrectomy, also to create standards for future evaluation of nephrectomies performed by minimal invasive techniques.Methods: We present a historical 20 years’ series of 646 consecutive nephrectomies performed in the period of 1978–1997. Malignant disease led to the operation in 437 cases, of which 98 were urothelial tumors in the renal pelvis or ureter. 209 kidneys were removed due to benign conditions. The incidence of nephrectomy for benign conditions has declined from 75 in the first 5–year period to 32 in the last.Results and Discussion: Postoperative complications occurred in 100 patients (15.5%). Nephrectomy for malignant disease had a significantly higher rate of complications than operations for benign conditions (p<0.001), especially hemorrhagic complications and pneumonias were more frequent. There were no differences as a result of the operative approach. Reoperation was carried out in 3.0% of the cases. Overall mortality rate (<30 days) was 3.1%.

1.
Kerbl K, Clayman RV, MacDougall EM, Gill IS, Wilson BS, Chandhoke PS: Transperitoneal nephrectomy for benign disease of the kidney: A comparison of laparoscopic and open surgical techniques. Urology 1994;43:607–613.
2.
Scott RF, Selzman HM: Complications of nephrectomy: Review of 450 patients and a description of a modification of the transperitoneal approach. J Urol 1966;95:307–312.
3.
Schiff M, Glazier WB: Nephrectomy: Indications and complications in 347 patients. J Urol 1977;118:930–931.
4.
Swanson DA, Borges PM: Complications of transabdominal radical nephrectomy for renal cell carcinoma. J Urol 1983;129:704–707.
5.
Nurmi MJ, Puntala PV, Tyrkko JE, Antila LE: Transabdominal and lumbar nephrectomy for renal adenocarcinoma. Scand J Urol Nephrol 1985;19:129–131.
6.
Blohme I, Fehrman I, NordÇn G: Living donor nephrectomy. Complication rates in 490 consecutive cases. Scand J Urol Nephrol 1992;26:149–153.
7.
Ruiz R, Novick AC, Braun WE, Montague DK, Stewart BH: Transperitoneal live donor nephrectomy. J Urol 1980;123:819–821.
8.
Ljungberg B, Alamdari FI, Holmberg G, Granfors T, Duchek M: Radical nephrectomy is still preferable in the treatment of localized renal cell carcinoma. Eur Urol 1998;33:79–85.
9.
Fowler JE: Failure of immunotherapy for metastatic renal carcinoma. J Urol 1986;135: 22–25.
10.
Neidhart JA, Murphy SG, Hennick LA, Wise HA: Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980;46:1128–1134.
11.
Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF: Diagnosis and management of renal cell carcinoma. Cancer 1971;28:1165–1177.
12.
Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297–301.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.